TITLE

Elan Buying into Theravance, GSK Royalty Stream for $1B

AUTHOR(S)
Sheridan, Cormac
PUB. DATE
May 2013
SOURCE
BioWorld Today;5/14/2013, Vol. 24 Issue 92, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that Elan Corporation plc, a biotechnology in Dublin, Ireland is placing a one billion dollar-stake on the respiratory franchise shared by Theravance Inc. and GlaxoSmithKline plc. The deal involves acquiring a 21 percent stake in Theravance's future royalties from four drugs that are partnered with the London-based GlaxoSmithKline. The four drugs and their approval by the U.S. Federal Drug Administration (FDA) are discussed.
ACCESSION #
87606219

 

Related Articles

  • Elan Buying into Theravance, GSK Royalty Stream for $1B. Sheridan, Cormac // BioWorld International;5/15/2013, Vol. 18 Issue 20, p1 

    The article discusses biotechnology firm Elan Corp.'s acquisition of a 21% stake in Theravance Inc.'s future royalty streams from four drugs partnered with London, England-based GlaxoSmithKline. One of the drugs Breo administered using the Ellipta inhaler just received its U.S. Food and Drug...

  • CNS News Round-Up.  // PharmaWatch: CNS;Jul2006, Vol. 5 Issue 7, p2 

    The article offers news briefs related to the pharmaceutical industry in the U.S. The Food and Drug Administration (FDA) has delayed the approval of migraine treatment drug, Trexima, from GlaxoSmithKline PLC. Biogen Idec Inc. and Elan Corp. PLC have announced to increase the price of multiple...

  • 'Lung' Time Coming: Breo Win Caps Theravance, GSK Efforts. Osborne, Randy // BioWorld Today;5/13/2013, Vol. 24 Issue 91, p1 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) for Breo (fluticasone furoate/vilanterol) for long-term treatment for chronic pulmonary obstructive disease from GlaxoSmithKline pPLC and Theravance Inc. which will be launched in the third quarter of 2013 under...

  • FDA ROUNDUP.  // MondayMorning;10/ 1/2012, Vol. 20 Issue 37, p1 

    The article offers information related to U.S. Food and Drug Administration (FDA) drug approval. It states that Bayer AG won approval for a new drug for advanced colon cancer, in which drug to be sold under the brand name Stivarga. It mentions that Theravance Inc. and GlaxoSmithKline PLC said...

  • Biogen Idec/Elan: Antegren could shake up MS treatment market.  // PharmaWatch: Monthly Review;August 2004, Vol. 3 Issue 8, p20 

    The U.S. Food and Drug Administration (FDA) has granted priority review status to Biogen Idec Inc. and Elan Corp PLC's multiple sclerosis (MP) drug Antegren. The prospect of faster FDA approval for Antegren is certainly good news for Elan and Biogen Idec, and confirms its potential to become the...

  • FDA asked to review Antegren.  // Inside MS;Oct-Dec2004, Vol. 22 Issue 4, p27 

    Reports on the U.S. Food and Drug Administration approval applied by Biogen Idec Inc. and Elan Corporations for their Antegren drug. Information on the monoclonal antibody Antegren or natalizumab; Mechanism of action of the drug; Application filed by sponsors for testing Antegren.

  • Biogen Idec/Elan: Antegren could shake up MS treatment market.  // PharmaWatch: Biotechnology;August 2004, Vol. 3 Issue 8, p10 

    The U.S. Food and Drug Administration (FDA) has granted priority review status to Biogen Idec Inc. and Elan Corp. PLC's multiple sclerosis (MP) drug Antegren. The prospect of faster FDA approval for Antegren is certainly good news for Elan and Biogen Idec, and confirms its potential to become...

  • Companies Look to Capture Part Of Growing Respiratory Market. Winter, Peter // BioWorld Insight;3/11/2013, Vol. 21 Issue 11, p1 

    The article discusses the companies in the growing respiratory market. Positive reviews was given on GlaxoSmithKline's cortiscosteroid by the U.S. Food and Drug Administration's (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC). Theravance $287.5 million debt for financing its partner GSK...

  • Tysabri poised for return to market.  // PharmaWatch: CNS;May2006, Vol. 5 Issue 5, p19 

    The article reports on Biogen Idec Inc. and Elan Corp. PLC's re-entry to the pharmaceutical market offering their multiple sclerosis treatment Tysabri with restrictions from the Food and Drug Administration (FDA). The company has withdrawn from the market after having a serious adverse events on...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics